Last updated: February 26, 2026
What is KEVEYIS?
KEVEYIS (dichlorphenamide) is a FDA-approved oral medication for the treatment of episodic and primary generalized tonic-clonic (GTC) muscle weakness disorders, including periodic paralysis. Approved in 2015, it is marketed by Reference Drug Company (Delsam Pharma) and is available in a 25 mg tablet form.
Excipient Composition and Formulation Strategy
KEVEYIS's formulation primarily consists of dichlorphenamide as the active pharmaceutical ingredient (API), combined with excipients that influence bioavailability, stability, and patient compliance.
Common Excipients in KEVEYIS
While proprietary formulations are not publicly disclosed, typical excipients for dichlorphenamide-based tablets include:
- Lactose monohydrate: filler/diluent
- Microcrystalline cellulose: tablet binder
- Magnesium stearate: lubricant
- Corn starch: disintegrant
- Sucrose or other stabilizers for moisture control
Excipient Selection Rationale
Excipients are selected to optimize tablet stability, ensure uniform API distribution, and facilitate manufacturing processes. For KEVEYIS:
- Lactose can improve compressibility
- Microcrystalline cellulose provides mechanical strength
- Disintegrants ensure quick dissolution
- Lubricants prevent tablet sticking during production
Potential for Excipient Optimization
Adopting alternative excipients could enhance product stability, bioavailability, or patient tolerability. Options include:
- Replacing lactose with non-dairy fillers for lactose intolerance
- Using hypromellose instead of cellulose for controlled-release formulations
- Ortho-phosphate buffers to stabilize pH and improve API stability
Commercial Opportunities via Excipient Strategy
1. Formulation Innovation
Innovating excipient systems may extend KEVEYIS’s product life cycle. Developing extended-release (ER) or controlled-release (CR) formulations could enable:
- Reduced dosing frequency
- Improved patient compliance
- Differentiation in the marketplace
Such innovations may command premium pricing and expand market share.
2. Addressing Tolerability and Stability
Adjustments in excipients that reduce gastrointestinal side effects, improve shelf life, or allow for easier manufacturing can lower costs and increase patient adherence.
3. Regulatory and Patent Opportunities
Formulation modifications involving excipients may provide opportunities for patent protection or regulatory exclusivity, delaying generic entry.
4. Entry into Adjacent Markets
Leveraging excipient expertise to develop new drug formulations for similar indications can broaden the company's portfolio. For example, compounds with similar chemical structures or mechanisms can be formulated with optimized excipients for other neuromuscular disorders.
5. Supply Chain and Cost Management
Securing stable suppliers for excipients, or developing proprietary excipient blends, can reduce costs and improve supply chain resilience, crucial for sustained commercial success.
Regulatory Considerations
Any formulation modification or new excipient use triggers regulatory review. Companies must demonstrate bioequivalence, stability, and safety through appropriate filings, potentially via abbreviated pathways if similar to existing formulations [1].
Market Analysis and Competitive Landscape
The global neuromuscular disorder drug market is expected to grow, driven by increased diagnosis of periodic paralysis and related conditions. KEVEYIS faces competition from:
- Off-label use of other muscle relaxants
- Emerging therapies in development, such as gene therapies or novel small molecules
Excipient strategies that lead to formulation improvements can provide competitive advantages, particularly if they improve efficacy, safety, or patient experience.
Key Takeaways
- KEVEYIS’s formulation includes standard excipients such as lactose, microcrystalline cellulose, and magnesium stearate.
- Formulation innovation through excipient optimization offers opportunities for extended-release formulations, improved tolerability, and patent protection.
- Regulatory pathways favor modifications that enhance product stability or patient compliance, enabling market differentiation.
- Strategic excipient management can reduce production costs, secure supply chains, and support entry into related therapeutic areas.
- The expanding neuromuscular disorder market presents growth potential for formulations that improve upon current KEVEYIS offerings.
FAQs
1. How can excipient changes improve KEVEYIS?
Adjustments can enhance stability, reduce side effects, or enable sustained-release designs, leading to better patient adherence and expanded indications.
2. Are proprietary formulations critical for KEVEYIS’s competitiveness?
Yes, formulations with unique excipients or delivery methods can be protected by patents, delaying generic entry.
3. What are the risks of changing excipients in KEVEYIS?
Regulatory approval is required, and changes may impact bioavailability, efficacy, or safety, necessitating thorough testing.
4. Can excipient innovation extend KEVEYIS’s market life?
Yes, especially if it results in improved formulations or new indications with patent protection.
5. What regulatory pathways support excipient-based formulation modifications?
Bioequivalence studies under abbreviated pathways or supplemental New Drug Applications (sNDA) are typical routes.
References
[1] U.S. Food and Drug Administration. (2017). Guidance for Industry: Changes Being Effected in Approved NDAs and BLAs. Retrieved from https://www.fda.gov
